Skip to main content
padlock icon - secure page this page is secure

Resolution of sinus bradycardia, high‐grade heart block, and left ventricular systolic dysfunction with rituximab therapy in Henoch‐Schonlein purpura

Buy Article:

$52.00 + tax (Refund Policy)

Henoch‐Schonlein purpura (HSP) is a rare, typically self‐limited, multi‐organ vasculitis. Cardiac involvement with HSP carries high morbidity and mortality, thus requiring early aggressive immunosuppressive therapy. We report a case of HSP complicated with acute systolic left ventricular (LV) dysfunction, symptomatic sinus bradycardia and high‐grade atrio‐ventricular (AV) heart block. Cyclophosphamide, a commonly used agent in HSP, was contraindicated due to the patient's presentation with acute renal failure. Treatment with monoclonal antibody rituximab and corticosteroids was initiated with an improvement in and resolution of LV systolic dysfunction, sinus bradycardia and AV block. We believe this is the first published report on rituximab treatment in HSP with cardiac involvement manifesting with severe LV systolic dysfunction, sinus bradycardia and high‐grade AV block.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Henoch‐Schonlein purpura; arrhythmia; heart block; left ventricular systolic dysfunction; rituximab; vasculitis

Document Type: Research Article

Publication date: July 1, 2018

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more